P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN’S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN DARATUMUMAB TRIALS

• K. Weisel,
• A. Chari,
• S. Z. Usmani,
• H. Goldschmidt,
• M.-V. Mateos,
• K. Qi,
• A. Londhe,
• S. Nair,
• X. Lin,
• L. Pei,
• E. Ammann,
• R. Kobos,
• J. Smit,
• T. Parekh,
• M. Slavcev,
• P. Moreau

Affiliations

K. Weisel

1 University Medical Center Hamburg-Eppendorf, Hamburg, Germany

A. Chari

2 Mount Sinai School of Medicine

S. Z. Usmani

3 Memorial Sloan Kettering Cancer Center, New York, United States of America

H. Goldschmidt

4 University Hospital Heidelberg and National Center of Tumor Diseases, Heidelberg, Germany

M.-V. Mateos

5 University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain

K. Qi

6 Janssen Research & Development, Titusville, United States of America

A. Londhe

6 Janssen Research & Development, Titusville, United States of America

S. Nair

7 Janssen Pharmaceutica NV, Beerse, Belgium

X. Lin

8 Janssen Global Services, Horsham

L. Pei

9 Janssen Research & Development

E. Ammann

10 Janssen Global Services, Raritan

R. Kobos

9 Janssen Research & Development

J. Smit

11 Janssen Research & Development, Spring House

T. Parekh

12 Janssen Research & Development, Bridgewater, United States of America

M. Slavcev

10 Janssen Global Services, Raritan

P. Moreau

13 Hematology Clinic, University Hospital Hotel-Dieu, Nantes, France